Skip to content

John M. Corkery

3 papers in the library · 434 citations · publishing 2005-2016

Papers

Novel psychoactive substances of interest for psychiatry

World Psychiatry February 1, 2016 Fabrizio Schifano, Laura Orsolini, G. Duccio Papanti et al. 319 citations

Novel psychoactive substances encompass a wide variety of drugs, including synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, dissociatives, piperazines, GABA receptor agonists, prescribed medications, psychoactive plants, and performance-enhancing drugs. Users are often drawn to them for intense psychoactive effects and their likely undetectability in routine drug tests. These substances act on neurotransmitter pathways such as dopamine, cannabinoid CB1, GABA-A/B, 5-HT2A, glutamate, and kappa opioid receptors—systems whose imbalance is linked to mental health conditions. The paper provides psychiatrists with updated knowledge on the clinical pharmacology and psychopathological consequences of these drugs, along with a brief overview of clinical management.

New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').

Journal of psychopharmacology (Oxford, England) November 1, 2005 Fabrizio Schifano, Paolo Deluca, Lisa Agosti et al. 70 citations

The compound 2C-T-7 ('Blue Mystic'), which resembles MDMA and other designer drugs, has rarely been identified in the EU, yet online discussion among experimenters has recently grown. A review of cyber and street market information found that 2C-T-7 was first synthesized in 1986 and produces desired effects of empathy and well-being, with anecdotal reports of hallucinations, nausea, anxiety, panic attacks, and paranoid ideation. Street-level availability in Europe appears very low, though one US death from mono-intoxication is documented. From an initial 360 websites, 118 were analyzed: 14 (11.9%) described synthesis, and 5 (4.2%) offered the drug for sale.

Methoxetamine‐related deaths in the UK: an overview

Human Psychopharmacology Clinical and Experimental July 1, 2015 Stefania Chiappini, Hugh Claridge, John M. Corkery et al. 45 citations

Methoxetamine (MXE), a novel psychoactive substance, was found in eight fatalities in the UK between 2011 and 2013. The median age at death was 27 years; most decedents were White and male. MXE was directly implicated in four deaths and likely contributed to two others, and in seven of eight cases it was used alongside other substances. The report calls for more research into MXE's health effects and toxicity, and for healthcare professionals to be aware of its harms to develop early interventions and reduce poisonings and deaths.